Polycystic Kidney Disease Market Forecasted to Surge in Coming Years

Strategic Insights -

Polycystic kidney disease, a genetic disorder that causes numerous fluid-filled cysts in the kidneys, is anticipated to see a significant rise in its market size, driven by the increasing prevalence and awareness of the disease. The market is expected to grow with a substantial CAGR during the study period (2020-2034). DelveInsight's report, "Polycystic Kidney Disease Market Insights, Epidemiology, and Market Forecast-2034," provides an in-depth analysis of the market dynamics, including the current and projected market size, key companies, and emerging therapies.

Key Takeaways:

  • The Polycystic Kidney Disease market size is anticipated to grow with a significant CAGR during the study period (2020-2034).
  • Regulus Therapeutics Inc. shared positive clinical and regulatory progress from its ADPKD program, highlighting promising topline data from an interim review of the fourth cohort in its Phase 1b Multiple Ascending Dose (MAD) study of farabursen (RGLS8429) for Autosomal Dominant Polycystic Kidney Disease (ADPKD).
  • Eloxx Pharmaceuticals, Inc. provided updates on its ELX-02 and ZKN-013 programs, including the Orphan Drug Designation (ODD) granted to ELX-02, which is being developed for treating Alport syndrome caused by nonsense mutations (NMAS).
  • The Polycystic Kidney Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period, as well as the launching of various multiple-stage Polycystic Kidney Disease pipeline products.
  • Polycystic Kidney Disease ranks as the fourth most common cause of kidney failure in the United States.
  • Autosomal Recessive Polycystic Kidney Disease is an uncommon type of the condition, affecting approximately 1 in every 25,000 children globally.
  • Research indicates that autosomal recessive polycystic kidney disease affects both males and females equally and is estimated to occur in about 1 in 20,000 people in the general population.

Statistics:

  • The Polycystic Kidney Disease market size is anticipated to grow with a significant CAGR during the study period (2020-2034).
  • 1 in 70 individuals carries a single mutation in the PKHD1 gene.
  • Around 1 in 25,000 children globally are affected by Autosomal Recessive Polycystic Kidney Disease.
  • Polycystic Kidney Disease ranks as the fourth most common cause of kidney failure in the United States.
  • The disease is estimated to occur in about 1 in 20,000 people in the general population.

Sources:

  • M2 PRESSWIRE-June 19, 2025-: Polycystic Kidney Disease Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Otsuka Pharma, Rege Nephro, Regulus Therapeutics, Hannover Medical School, Rege Nephro (C)1994-2025 M2 COMMUNICATIONS RDATE:19062025
  • DelveInsight's "Polycystic Kidney Disease Market Insights, Epidemiology, and Market Forecast-2034'' report.
  • Regulus Therapeutics Inc. (Nasdaq: RGLS) press release.
  • Eloxx Pharmaceuticals, Inc. (OTC: ELOX) press release.